Fragmentation Vs Dusting With FANS for Renal Stones Less Than 2cm: A Randomized Controlled Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBir Hospital

About this trial

The use of FANS has changed the operative landscape of RIRS by allowing continuous active suction-assisted clearance of ablated stone material in real time. Use of fragmentation technique in FANS requires high-energy to reduce stone burden into small fragments, followed by active suction of residual fine material. Dusting with FANS, on the other hand, converts the entire stone volume into sub-millimetre particulate that is continuously suctioned away during lasing potentially offering a more streamlined workflow with potentially less energy usage, reduced mechanical stress on the ureteroscope working channel, and fewer scope withdrawals. The combination of TFL dusting with FANS-assisted real-time evacuation may produce stone-free outcomes equivalent or superior to fragmentation, while offering these additional operative efficiencies.

Whether dusting using TFL with FANS is non-inferior or indeed superior to fragmentation using TFL with FANS in terms of stone-free rate at one month has not been evaluated in prospective randomised trial yet. This study aims to answer that specific question in patients with renal stone less than 2 cm.

Eligibility criteria

Qualifiers

Age ≥18 years

Renal stone(s) confirmed on non-contrast CT KUB

Total stone less than 2cm

Stone amenable to flexible ureterorenoscopy (FURS)

Disqualifiers

Active urinary tract infection (positive urine culture) at time of planned surgery

Anatomical anomalies precluding safe FURS (e.g., infundibular stenosis, severe calyceal diverticulum inaccessible to flexible scope)

Pregnancy or breastfeeding

Prior ipsilateral renal surgery within 3 months of enrollment

Trial design

Treatments tested in this trial

  • Dusting
  • Fragmentation

Treatment groups

86 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators